Trump has a 'small personal financial interest' in hydroxycholorquine drugmaker. Allies have bigger stakes.
President Trump has been promoting the malaria and lupus drug hydroxychloroquine to treat COVID-19 "with all of the enthusiasm of a real estate developer," even as the medical experts on his coronavirus task force have repeatedly "warned against overselling a drug yet to be proved a safe remedy, particularly for heart patients," The New York Times reports. Some hospitals in Sweden stopped using hodroxycholoriquinine to treat the coronavirus due to adverse side effects, and the International Society of Antimicrobial Chemotherapy rejected a positive French study it had published on the drug, cited by Trump.
Dr. Anthony Fauci, the top U.S. infectious disease officials, has warned publicly and privately against promoting the drug absent studies showing its effectiveness, and "behind the scenes, career health officials have raised even stronger warnings about the risk to some Americans' heart health and other complications, but been warned not to publicly speak out and potentially contradict Trump," Politico reports. "Trump's focus on the drugs ... has increasingly warped his administration's response. Health officials have been told to prioritize the anti-malaria drugs over other projects that scientists believe have more potential to fight the outbreak." So...
"If hydroxychloroquine becomes an accepted treatment, several pharmaceutical companies stand to profit, including shareholders and senior executives with connections to the president," the Times reports. "Trump himself has a small personal financial interest in Sanofi, the French drugmaker that makes Plaquenil, the brand-name version of hydroxychloroquine." Other top Trump donors, allies, golf buddies, and Cabinet officials also have various ties to hydroxychlorquine.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
On the other hand, some hospitals in New York are using the drug to treat COVID-19, with mixed results. Senior administration officials tell Politico that Trump really believes hydroxychloroquine could end the COVID-19 pandemic. Trump has told associates Oracle founder Larry Ellison first pointed him to the drug, and TV personality Dr. Mehmet Oz, Rudy Giuliani, and trade adviser Peter Navarro have boosted his faith. "He thinks that it's the drug that's going to get everyone back to work," one Republican close to the White House told Politico, joking: "Do you have a supply?"
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
China and India's dam war in the Himalayas
Under The Radar Delhi's response to Beijing's plans for a huge dam in Tibet? Build a huge dam of its own right nearby
By Chas Newkey-Burden, The Week UK Published
-
Born this way
Opinion 'Born here, citizen here' is the essence of Americanism
By Mark Gimein Published
-
What does Trump's immigration crackdown mean for churches?
Today's Big Question Mass deportations come to 'sacred spaces'
By Joel Mathis, The Week US Published
-
Chinese AI chatbot's rise slams US tech stocks
Speed Read The sudden popularity of a new AI chatbot from Chinese startup DeepSeek has sent U.S. tech stocks tumbling
By Peter Weber, The Week US Published
-
Five years on, can Labour's reset fix Brexit?
Today's Big Question Keir Starmer's revised deal could end up a 'messy' compromise that 'fails to satisfy anyone'
By The Week UK Published
-
Penny-pinching: Elon Musk looks at the cent to cut costs
In the Spotlight Musk's DOGE claims that millions can be saved if production on pennies is slashed
By Justin Klawans, The Week US Published
-
Is inflation about to surge again?
Talking Points The Federal Reserve is cautious about Trump's policies
By Joel Mathis, The Week US Published
-
US port strike averted with tentative labor deal
Speed Read The strike could have shut down major ports from Texas to Maine
By Peter Weber, The Week US Published
-
Biden expected to block Japanese bid for US Steel
Speed Read The president is blocking the $14 billion acquisition of U.S. Steel by Japan's Nippon Steel, citing national security concerns
By Peter Weber, The Week US Published
-
How long will Social Security remain solvent?
Today's Big Question And what can be done to fix its current precarious situation?
By Joel Mathis, The Week US Published
-
What does the FDIC do?
In the Spotlight Deposit insurance builds confidence in the banking system
By Joel Mathis, The Week US Published